Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. - Wikidata - awgldk - TriplyDB

Binding of levosimendan, a calcium sensitizer, to cardiac troponin C.

Binding of levosimendan, a calcium sensitizer, to cardiac troponin C.

http://www.wikidata.org/entity/Q30632646

about

The inotropic effect of the active metabolite of levosimendan, OR-1896, is mediated through inhibition of PDE3 in rat ventricular myocardium A structural and functional perspective into the mechanism of Ca2+-sensitizers that target the cardiac troponin complex Ca(2+)-regulated structural changes in troponin Targeting the sarcomere to correct muscle function Defining the binding site of levosimendan and its analogues in a regulatory cardiac troponin C-troponin I complex Structure and function of cardiac troponin C (TNNC1): Implications for heart failure, cardiomyopathies, and troponin modulating drugs Effect of levosimendan in experimental verapamil-induced myocardial depression.Desensitization of myofilaments to Ca2+ as a therapeutic target for hypertrophic cardiomyopathy with mutations in thin filament proteins.Effects of the calcium sensitizer OR-1896, a metabolite of levosimendan, on post-infarct heart failure and cardiac remodelling in diabetic Goto-Kakizaki rats Predicting cardiomyopathic phenotypes by altering Ca2+ affinity of cardiac troponin C.Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties.Molecular actions of drugs that sensitize cardiac myofilaments to Ca2+.Levosimendan: implications for clinicians.Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.Levosimendan for the treatment of acute heart failure syndromes.Fluorescence Based Characterization of Calcium Sensitizer Action on the Troponin Complex.Interaction of cardiac troponin with cardiotonic drugs: a structural perspective.Ryanodine receptor-mediated arrhythmias and sudden cardiac death.Comparison of single-dose and repeated levosimendan infusion in patients with acute exacerbation of advanced heart failure.Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomised trials.Probing the mechanism of cardiovascular drugs using a covalent levosimendan analog.Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart.Rapid recovery from acute myocarditis under levosimendan treatment: report of two cases.Positive inotropic effect of levosimendan is correlated to its stereoselective Ca2+-sensitizing effect but not to stereoselective phosphodiesterase inhibition.The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine.Levosimendan protects against experimental endotoxemic acute renal failure.Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs.Successful Identification of Cardiac Troponin Calcium Sensitizers Using a Combination of Virtual Screening and ROC Analysis of Known Troponin C Binders.Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure.Use of Levosimendan in Postoperative Setting After Surgical Repair of Congenital Heart Disease in Children.

P2860

Q21131829-643B0B02-1366-4719-A52D-1257942ADF6D Q27664209-1307492E-03C2-4A53-870F-B8BCEAABA20A Q28241337-ACF2C335-D66A-4EB2-A091-EC93E5074B97 Q28260629-16FC27BC-09DD-48CF-A94D-667799608378 Q28284695-93FF6E2A-D89A-4B8F-A20D-6A11BB92D1AD Q28607749-E19938C8-0102-4455-8342-9AF3FF3DF284 Q33763274-A12C5937-5283-48E8-9BEC-CEE95334520A Q33771564-C0F5B185-1E38-40F5-B6A8-B49B8876AEBB Q33812788-65AA55E9-18C3-4E55-838D-2C9AE654E3D1 Q34107285-5FB98E7C-3C1D-40C6-9837-2877A20D145F Q34232063-778D78DB-759C-4E3D-9224-2AA3A690EF51 Q34952145-FC1E6775-5FC4-4736-9E0C-E35B9203A972 Q35546635-F297F969-0BAA-4791-8635-AC27899CDA59 Q35706799-604B2D11-D341-4955-A125-7D85DD455AEA Q36284075-DC832F72-5C98-46AB-B33E-AB3F58128001 Q36326272-45EBB4CF-A80A-48C9-89A9-6F96F6110EC7 Q36479750-22649534-D6F6-4EDD-A2C6-67CA2C2653DF Q36595569-B51617A8-F7AD-4A70-94A4-6032FB781C1C Q37248371-A321C19C-5B42-4307-BA0A-8DBD6F2772DC Q37607413-0E73150D-320A-4E5F-B9CF-F353EFDC9B87 Q38099679-0AC8C95E-C494-4DD7-9FCB-B8E94A5B0828 Q38173852-529A031B-8FFC-443C-B877-9362E6557179 Q40151421-26A56A1C-994A-4F12-8BAB-B71C3F99BF7F Q42198249-8DDAFEF3-A216-4691-BD74-145F8696D93B Q43667587-DBDD9927-8ADA-46EF-A27F-893BC2014906 Q46404003-1E84A151-1489-46B1-B91C-37EA6C9266D6 Q46515116-94255C32-CEF8-4D18-94C5-FE2880C5C2F4 Q46897966-3C8BD311-A3B7-49A1-B26B-12D4D3F7F86B Q46915198-01B7EB40-9654-4B49-B0B6-2E02F174B485 Q47396402-7F671FD5-AA30-440B-9DC6-A64B377D01B4 Q48475898-6A43A799-B545-4516-915D-E355D01A1F7A Q50201548-75E6E79A-9259-4DCB-AADE-AA25CED5B975

P2860

Binding of levosimendan, a calcium sensitizer, to cardiac troponin C.

http://www.wikidata.org/entity/Q30632646

description

2000 nî lūn-bûn

@nan

2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Binding of levosimendan, a calcium sensitizer, to cardiac troponin C.

@ast

Binding of levosimendan, a calcium sensitizer, to cardiac troponin C.

@en

type

label

Binding of levosimendan, a calcium sensitizer, to cardiac troponin C.

@ast

Binding of levosimendan, a calcium sensitizer, to cardiac troponin C.

@en

prefLabel

Binding of levosimendan, a calcium sensitizer, to cardiac troponin C.

@ast

Binding of levosimendan, a calcium sensitizer, to cardiac troponin C.

@en

P1433

Q30632646-6C691DB2-607E-4CFD-8A47-32C2CC1D941E

P1476

Q30632646-51B8ED9B-0638-40D9-98B6-66B4D3F0CC65

P2093

Q30632646-1F4D81FA-D777-4EFA-92B7-1C4AB9DB4194

Q30632646-2BAD0D5B-83C9-41EF-8A6E-8C0A72566537

Q30632646-50C25BEB-6EF0-437E-BC41-F57D945D3097

Q30632646-6C094C7F-0609-4D0C-A6E8-F2376B4B47BF

Q30632646-78354E44-7AED-4116-AEF7-E95C6DF34F80

Q30632646-8FC91B31-D911-466F-AB7C-0A8391548252

Q30632646-967498FE-82DE-458E-83BF-9ABCA3716D59

Q30632646-9B79F573-EEE4-45B4-857F-CD371626E201

Q30632646-BAAD74DA-CF73-490B-B169-16E4687C72DC

Q30632646-C48B9736-CAA5-4056-99AA-F91033316F2A

P2860

Q30632646-114092F5-1960-454A-B659-AC273C06E4D1

Q30632646-16973326-5566-4DA5-89F1-4D535CBA24C3

Q30632646-1DF04827-BEF8-43FE-A515-EEB2A3968F03

Q30632646-3A50B1F5-EB1A-415C-BCE9-6269BB48AFDF

Q30632646-3CE3B261-CED4-4FBF-9E33-2871284F61DC

Q30632646-417F4EA4-3CF9-47FD-82FC-CC8C0974306B

Q30632646-45661D17-98E9-4BC9-ACDD-BBA0AA76C32C

Q30632646-4F4C60A1-97CE-4065-8E7D-1FB5A3B95B8E

Q30632646-4F4C7847-041B-42CD-AB0F-A5CF399C6065

Q30632646-5E6D06A5-08C5-4D08-9363-6EFC48D99FBB

P304

Q30632646-403A4FF5-7C87-40AE-A120-BA7ADF6C719D

P31

Q30632646-8D707F7D-B022-4547-BEA0-9CEED533E78E

P356

Q30632646-8F55529F-AF7C-41C2-A28B-F8E5B7058568

P407

Q30632646-1B514BC5-EF32-4822-B2BC-0C5092B8BEA7

P433

Q30632646-235507D9-5250-451F-A0CA-6BCF1C6313E0

P478

Q30632646-B8821FFD-8A1B-4E8E-B0A7-AA08D0DF681C

P577

Q30632646-155577CB-195C-45A9-9F68-6C55C5B91750

P5875

Q30632646-71403A27-288B-43B8-9B17-F4A9B522A289

P698

Q30632646-BE1651A9-B79C-4ECB-A8DB-FA7D01B23CBD

P356

P1433

Journal of Biological Chemistry

P1476

Binding of levosimendan, a calcium sensitizer, to cardiac troponin C.

@en

P2093

Abbott MB

http://www.w3.org/2001/XMLSchema#string

Abusamhadneh E

http://www.w3.org/2001/XMLSchema#string

Annila A

http://www.w3.org/2001/XMLSchema#string

Drakenberg T

http://www.w3.org/2001/XMLSchema#string

Heikkinen S

http://www.w3.org/2001/XMLSchema#string

Kilpelainen I

http://www.w3.org/2001/XMLSchema#string

Laakso T

http://www.w3.org/2001/XMLSchema#string

Pollesello P

http://www.w3.org/2001/XMLSchema#string

Rosevear PR

http://www.w3.org/2001/XMLSchema#string

Serimaa R

http://www.w3.org/2001/XMLSchema#string

P2860

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

Binding of cardiac troponin-I147-163 induces a structural opening in human cardiac troponin-C

Bepridil opens the regulatory N-terminal lobe of cardiac troponin C

Structure of cardiac muscle troponin C unexpectedly reveals a closed regulatory domain

Calcium-induced structural transition in the regulatory domain of human cardiac troponin C

1H, 13C and 15N chemical shift referencing in biomolecular NMR

Drug binding to cardiac troponin C

Discovering high-affinity ligands for proteins: SAR by NMR

Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: structure-response and binding analysis with analogs of levosimendan.

High-throughput nuclear magnetic resonance-based screening.

P304

9337-9343

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M007484200

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

276

http://www.w3.org/2001/XMLSchema#string

P577

2000-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12215276

http://www.w3.org/2001/XMLSchema#string

P698

11113122

http://www.w3.org/2001/XMLSchema#string